PPARG and colorectal carcinoma: Given that a potential crosstalk mechanism between PPARγ and Wnt/β-catenin regulates CRC progression, this offers a promising avenue for the development of novel PPARγ agonists that inhibit the Wnt/β-catenin signaling pathway [102].